Background: Breast cancer is still a global public health problem, especially in women and is the second leading cause of death after lung cancer. Indonesia is a country with a high incidence of breast among women. Methods: This study used a retrospective study of breast cancer patients registered at Division of Surgical Oncology in Indonesia. Information about demographic, clinical and pathological characteristics of patients for a period of 5 years (2014 to 2020) were collected and described. Results: Information for 1260 cases of breast cancer who underwent IHC examination with an average age of 53.73 years of patients, with the most age above 50 years (63.6%) were collected. On IHC examination, 58.6% positive estrogen receptors were found, positive progesterone receptors were 55.4%, Her2 was positive 37.7% and high Ki67 protein was 56.9%. The most common breast cancer subtypes were luminal B (43.2%), followed by luminal A (21.7%), TNBC (18.1%), and Her2 (17%), with the highest stages being IIIB (31.7%).Conclusions: The breast cancer was presented at higher stage, with more cases with estrogen or progesterone receptors are positive with low frequency of Her2 positivity and high in Ki67 protein expression.

Lung cancer is known as the most common malignancy in the world in terms of incidence and death rate. GLOBOCAN data in 2018 showed that its prevalence reaches 11.6% with mortality reaching 1.7 million annually. The prevalence of lung cancer in Indonesia is also considerably high; there were 25,332 cases in men and 9,374 cases in women with mortality reaching 308,660 people. In general lung cancer is classified as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Although it is less common, SCLC has a worse prognosis with a 5 year survival rate of 6.4%. In addition, SCLC is also often diagnosed when it has metastasized or already reaced extensive stage (ES-SCLC). Although SCLC is classified as chemo-responsive cancer, the overall outcome of first-line and second-line therapy is still unsatisfactory with an ORR of 10-25%. One of characteristic of SCLC is genomic instability which relates to high level of mutations especially EGFR mutation that strongly correlate with therapeutic outcome. Therefore, targeting EGFR mutation is a sensible and potential field in developing SCLC therapy. EGFR-CpG-ODN nanovaccine is one of the potential therapeutic choices that exploit this mutation. EGFR CpG ODN nanovaccine could inhibit resistance to EGFR TKI, increased dendritic cell maturation, inhibit cancer cell proliferation and apoptosis, as well as enhance the anticancer immune response. Therefore, this therapeutic approach is a promising future therapy for SCLC petients that could improve patient’s survivability.

Background: Chemotherapy-induced neutropenia (CIN) is chemotherapy's most frequent myelosuppression effect. Previous studies have examined static prognostic factors to assess dynamic neutrophil changes in each cycle. This study focuses on post-chemotherapy monocytopenia as a more dynamic predictor of CIN. This research aimed to know whether post-chemotherapy monocytopenia can be used as a predictor of CIN in breast cancer patients undergoing the chemotherapy cycle. Methods: This research used a prospective and a retrospective longitudinal cohort of breast cancer patients undergo a CAF regimen at Sanglah Hospital Denpasar. The research was conducted on 30 samples for three cycles (90 total cycles). Monocyte data is taken in the first week (days 4 to 9), and neutrophil data is taken in the second week (days 10 to 16). Results: From statistical analysis with interval data scale, we obtained that p 0.001 with Pearson correlation 0.613 for cycle 1, p 0.001 with Pearson correlation 0.611 for cycle 2, and p 0.003 with Pearson correlation 0.522 for cycle 3. Conclusions: In conclusion, post-chemotherapy monocytopenia can be used to predict the occurrence of chemotherapy-induced neutropenia (CIN) with the strongest positive correlation in the first cycle.

Identifying intracranial lesions in patients with maxillofacial injuries is crucial to improving survival. The purpose of this study was to compile a predictive index of the occurrence of intracranial lesions based on age, location of trauma, and cause of injury in maxillofacial trauma patients. An analytical observational study with a retrospective cohort design. Bivariable analysis and Multivariate analysis using SPSS IBM 26. The value of p<0.005 is significant. There were 81 subjects with maxillofacial trauma with intracranial lesions. Most of the samples were 25 years old (71.6%). Meanwhile, based on the location of the fracture, most of the subjects suffered from Le Fort I, Le Fort II, or a combination of both (70.4%). Only 12.3% of subjects had Le Fort III fractures (with or without Le Fort I or II fractures), and only 17. 3% had concurrent Le Fort II and III fractures. As for 80.2% of the subjects suffered injuries caused by traffic accidents. Intracranial lesions were found in 59.3% of subjects with predominant EDH (21%). Age 25 years increased the risk of intracranial lesions with adjusted OR 19.77 (95% CI 3.77–103.67). Le Fort II & III fractures adjusted OR of 52.68 (95%CI 2.50–112.188). Traffic accident an adjusted OR of 16.75 (95%CI 2.83–99.29). There was a significant and independent relationship between age 25 years, location of Le Fort II & III fractures, and traffic accidents as a cause of injury with intracranial lesions in patients with maxillofacial fractures.